Sign Up to Receive Your Personalised Learning Resources
Start Learning
PSMA-targeted radiopharmaceuticals: An evolving approach to prostate cancer management
Ken Kato, ASCO 2023: Highlights in upper gastrointestinal cancers
Sara Tolaney, ASCO 2023: Highlights from the NATALEE trial of ribociclib and endocrine therapy in the treatment of breast cancer
Higher-risk MDS and AML: How new guidelines are changing diagnosis, classification and management
Arnulf Stenzl: Pivotal new projects of the European Association of Urology (EAU)
Connecting Symptoms to Quality of Life: The Importance of Considering Patient Wellbeing when Managing Cutaneous T-Cell Lymphoma (CTCL)
Carmelo Rizzari: Highlights from the SIOPE Europe 2023 Annual Meeting!
New and emerging agents in HER2-negative metastatic breast cancer: Implications for current and future practice
Sacituzumab Govitecan for the Treatment of HR+/HER2- Breast Cancer in Heavily Pre-treated Patients
Teclistamab Monotherapy for the Treatment of Adult Patients with Relapsed and Refractory Multiple Myeloma
Sign up to view Favourites, Keep Notes and Track CME Credits
Favourites
Futibatinib for the Treatment of Previously Treated, Unresectable, Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma with Fibroblast Growth Factor Receptor 2 (FGFR2) Gene Fusions or Other Rearrangements
View
Adverse event identification and management in locally advanced/metastatic urothelial carcinoma
View
Sunil Singhal, AACR 2023: Intraoperative molecular imaging as a tool in cancer surgery
View
Highlights in breast cancer – KEYNOTE-756, Checkmate-7FL, TOPION-Breast01, monarchE: Sara Tolaney, ESMO 2023
View
Robin Foà, EHA 2023: New developments in the treatment of Philadelphia-positive acute lymphoblastic leukaemia
View
Cancer prevention and the power of breastfeeding: PrEvCan | Celia Diez de los Rios
View
Carmelo Rizzari: An overview of SIOP Europe
View
Arnulf Stenzl: Highlights from EAU23!
View
Practical considerations for personalized medicine in thyroid cancer: Which therapies are suited to particular patient profiles?
View
The evolving treatment landscape in relapsed/refractory multiple myeloma
View